Anthropic has completed the acquisition of Coefficient Bio, a New York based stealth AI biotech startup founded in 2025, in an all stock deal valued at approximately $400 million. The move strengthens Anthropic’s growing focus on AI applications in healthcare, life sciences, and drug discovery.
Glimpse:
The tiny startup, which had fewer than 10 employees many of them former Genentech computational biology researchers will join Anthropic’s healthcare and life sciences division. Coefficient Bio specialized in developing AI models to tackle complex biological research challenges and improve efficiency in drug discovery. This acquisition builds on Anthropic’s recent launch of Claude for Life Sciences and its broader efforts to apply advanced AI across preclinical research, clinical operations, and regulatory strategy in the biotech sector.
The acquisition highlights Anthropic’s strategic ambition to expand its presence in the intersection of artificial intelligence and biotechnology. By integrating Coefficient Bio’s expertise, particularly from team members with strong backgrounds in computational biology, Anthropic aims to enhance its capabilities for handling intricate biotech workflows. These range from research planning and target identification to streamlining clinical development and regulatory processes, ultimately supporting faster and more effective scientific breakthroughs.
This move comes shortly after Anthropic introduced Claude for Life Sciences, an initiative designed to assist researchers with complex analysis and discovery tasks. The company has been actively building new features tailored for the life sciences industry, covering everything from early stage R&D to real world clinical and regulatory applications. The addition of Coefficient Bio’s talent and technology is expected to accelerate these efforts and position Anthropic more strongly in the rapidly evolving AI-driven healthcare landscape.
With the biotech AI space attracting significant attention, this deal underscores the high value being placed on specialized domain expertise combined with frontier AI models. It reflects growing confidence that general purpose AI systems, when augmented with deep biological knowledge, can play a transformative role in addressing long standing challenges in drug development and personalized medicine.
“The acquisition brings a team of fewer than 10 people, nearly all former Genentech computational biology researchers, into Anthropic’s healthcare and life sciences division… staking real capital on the idea that general-purpose AI can accelerate drug discovery.”
By
HB Team
Related News
